急性B型主动脉夹层早期胸主动脉腔内修复与药物治疗后的再入院比较
多中心回顾性研究纳入2015至2020年急性B型主动脉夹层患者216例,其中无并发症169例,49%接受药物治疗、51%接受早期胸主动脉腔内修复。药物治疗组非计划再入院率34%对9%(P=0.0001)、手术率28%对8%(P=0.0007)均更高,住院时间更短(6.3对13.1天,P<0.0001);两组死亡率无差异,药物治疗组心肌梗死率更高(10.8%对2.3%,P=0.02)。
要点
- 无并发症急性B型主动脉夹层中,药物治疗组再入院率34%高于早期TEVAR组9%(P=0.0001)。
- 药物治疗组非计划手术率28%高于TEVAR组8%(P=0.0007),住院时间更短(6.3对13.1天)。
- 两组1年死亡率无差异,药物治疗组心肌梗死率更高(10.8%对2.3%,P=0.02)。
核心结论
- 急性无并发症B型主动脉夹层药物治疗与更高的再入院率和非计划手术需求相关,但药物治疗失败者1年死亡率与早期TEVAR无差异。
- 半数患者接受药物治疗、半数接受早期TEVAR,提示该人群存在临床均衡,作者认为需要更大规模随机试验来确定早期TEVAR是否有明确获益。
研究设计与样本
- 多机构回顾性综述,纳入2015至2020年急性B型主动脉夹层且有1年结局的患者,排除既往主动脉干预或慢性、医源性或创伤性病因者。
- 共216例患者来自两家大型学术中心,其中复杂47例、无并发症169例;无并发症者中83例(49%)初始接受药物治疗、86例(51%)接受TEVAR。
- 主要暴露为初次入院时TEVAR与药物治疗,主要结局为初次入院后非计划再入院和/或手术,采用双变量和多变量logistic回归分析。
主要发现
- 药物治疗组非计划再入院率34%对TEVAR组9%(P=0.0001),手术率28%对8%(P=0.0007),住院时间6.3天对13.1天(P<0.0001)。
- 两组死亡率无差异,药物治疗组心肌梗死率10.8%对TEVAR组2.3%(P=0.02)。
- 药物治疗组28% later需要手术,其发病率和死亡率与初始TEVAR患者相似。
- 初始药物治疗与非计划再入院相关(比值比8.3,P=0.02),与需要手术相关(比值比4.56,P=0.006)。
- 按累及主动脉分区分析,结局无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of thoracic endovascular aortic repair (TEVAR) for the management of acute uncomplicated type B aortic dissection (TBAD) has increased. Although the results from early studies were promising, larger randomized trials evaluating TEVAR are lacking. It is also unclear where sufficient equipoise exists for such trials. In the present study, we evaluated the number of readmissions and unplanned operations after TEVAR vs those after medical management as the initial treatment of acute uncomplicated TBAD and the frequency of each treatment in this population. METHODS: We performed a multi-institutional retrospective review of patients with acute TBAD from 2015 to 2020 with the 1-year outcomes available, excluding patients with prior aortic intervention or chronic, iatrogenic or traumatic etiologies. The primary exposure was TEVAR vs medical management at the index admission. The patient demographics, clinical presentation, and imaging findings were analyzed using bivariate and multivariate logistic regression for the primary outcomes of unplanned readmission and/or operation after the initial admission. The secondary outcomes were mortality, myocardial infarction, stroke, renal failure requiring dialysis, retrograde type A dissection, and length of stay. We hypothesized that the readmissions would be higher with medical management. RESULTS: A total of 216 patients with TBAD (47 with complicated and 169 with uncomplicated) from two large academic centers were identified. Of the 169 patients with uncomplicated TBAD, 83 (49%) had been treated medically and 86 (51%) had undergone TEVAR at the initial admission. No differences were found in the demographics or high-risk imaging features at presentation. The medically managed patients had had higher rates of unplanned readmission (34% vs 9%; P = .0001) and operation (28% vs 8%; P = .0007) but shorter lengths of stay (6.3 vs 13.1 days; P < .0001). No differences were found in mortality, although the rate of myocardial infarction was higher in the medically managed group (10.8% vs 2.3%; P = .02). Although 28% of the medically managed patients had later required operation, they had had morbidity and mortality similar to those of patients who had undergone initial TEVAR. Initial medical management was associated with unplanned readmission (odds ratio, 8.3; P = .02) and the need for operation (odds ratio, 4.56; P = .006). No differences were found in the outcomes according to the involved aortic zones. CONCLUSIONS: In the present study, medical management of acute uncomplicated TBAD was associated with higher rates of readmission and the need for unplanned operation compared with TEVAR. However, no differences were found in the 1-year mortality for the patients for whom medical management had failed. Because one half of the patients had undergone medical management and one half had undergone early TEVAR, this finding suggests clinical equipoise for the treatment of acute uncomplicated TBAD. Therefore, a larger randomized trial appears warranted to determine whether a clear benefit exists for early TEVAR.
引用
- Yi JA, Gupta R, Tat Q, et al. Readmission after early thoracic endovascular aortic repair versus medical management of acute type B aortic dissection. J Vasc Surg. 2023. PMID: 36646334. doi:10.1016/j.jvs.2022.12.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。